Kahira Pharmaceuticals profits grow 22.5% in 6 months

ArabFinance: Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 22.47% year-on-year growth in net profit after tax for the first half (H1) of fiscal year (FY) 2021/2022, according to the company’s unaudited financial indicators filed to the Egyptian Exchange (EGX).

CPCI’s net profit after tax stood at EGP 82.05 million for the six-month period ended December 31^st 2021, compared to profits of EGP 67.004 million the year before, as per the statement.

Revenue amounted to EGP 527.10 million in H1 FY 2021/2022, down from EGP 532.23 million in the comparative period a FY earlier.

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an as is and as available basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.